IGI Logo

Below is quote on Gland pharma reported a good set of numbers for Q1FY22 by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd   

Gland pharma reported a good set of numbers for Q1FY22

Gland pharma limited reported revenue from operation at ₹1153 crores up by 31% as compared to ₹884.2 crores in Q1FY21. Companies core market has reported revenue growth of 16% YoY as strong performance in existing products as well as new products launch.

The domestic market has reported revenue growth of 77% YoY as the company has added new capacity and some benefits of remdesivir and Enoxaparin.

Companies reported gross margin at 54% as against 64% in Q1FY21 as in Q1FY21 company got some one-time benefits.

EBITDA was at ₹498.1 crores up by 12% as compared to ₹444.7 crores in Q1FY21 and margins drop from 49% to 41%.

The company reported a profit after tax of ₹350.7 crores in Q1FY2022, up by 12% as compared to 313.6 crores in Q1FY21.

The overall company a reported good set of numbers, we expect the company to continue its export market growth momentum but the Indian market may be flat for the year as all the benefits related to covid will not be there in upcoming quarters. We have a positive outlook on Gland Pharma Limited.

Above views are of the author and not of the website kindly read disclaimer